Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions

Vincent Pons, Deborah Greenspan, Francina Lozada-Nur, Laurie McPhail, Joel E. Gallant, Allan Tunkel, Caroline C. Johnson, James McCarty, Helene Panzer, Marcia Levenstein, Annclla Barranco, Stephen Green

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 167 human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily). At day 14, 87% of the fluconazole- treated patients were clinically cured, as opposed to 52% in the nystatin- treated group (P <.001). Fluconazole eradicated Candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (P <.001). The fluconazole group had fewer relapses noted on day 28 (18%, vs. 44% in the nystatin group; P <.001). This relapse difference no longer existed by day 42. Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.

Original languageEnglish (US)
Pages (from-to)1204-1207
Number of pages4
JournalClinical Infectious Diseases
Volume24
Issue number6
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions'. Together they form a unique fingerprint.

Cite this